The FDA's April 2026 reclassification of BPC-157 and 11 other peptides from Category 2 to Category 1 under HHS direction marked the initial step toward potential inclusion on the 503A Bulk Drug Substances List for pharmacy compounding. In July 2026, the Pharmacy Compounding Advisory Committee voted 8-6 to recommend adding BPC-157 despite FDA staff objections citing insufficient human clinical data, limited safety evidence, and immunogenicity risks. This non-binding advisory vote triggers a formal notice-and-comment rulemaking process that typically requires 12-24 months, with no final FDA determination or published rule reported as of late August 2026. Traders monitor the agency's follow-through on the recommendation, any public comment period developments, and broader policy signals on compounding access versus full drug approval pathways.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · AggiornatoNUOVO
31 ago 2026
31 agosto 2026
1%
31 dicembre 2026
48%
$3,582 Vol.
31 agosto 2026
$1,849 Vol.
1%
31 dicembre 2026
$1,733 Vol.
48%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's April 2026 reclassification of BPC-157 and 11 other peptides from Category 2 to Category 1 under HHS direction marked the initial step toward potential inclusion on the 503A Bulk Drug Substances List for pharmacy compounding. In July 2026, the Pharmacy Compounding Advisory Committee voted 8-6 to recommend adding BPC-157 despite FDA staff objections citing insufficient human clinical data, limited safety evidence, and immunogenicity risks. This non-binding advisory vote triggers a formal notice-and-comment rulemaking process that typically requires 12-24 months, with no final FDA determination or published rule reported as of late August 2026. Traders monitor the agency's follow-through on the recommendation, any public comment period developments, and broader policy signals on compounding access versus full drug approval pathways.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Mercato aperto: Jun 22, 2026, 10:10 PM ET
Volume
$3,582Data di fine
1 gen 2027Mercato aperto
Jun 22, 2026, 10:10 PM ETRisolutore
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's April 2026 reclassification of BPC-157 and 11 other peptides from Category 2 to Category 1 under HHS direction marked the initial step toward potential inclusion on the 503A Bulk Drug Substances List for pharmacy compounding. In July 2026, the Pharmacy Compounding Advisory Committee voted 8-6 to recommend adding BPC-157 despite FDA staff objections citing insufficient human clinical data, limited safety evidence, and immunogenicity risks. This non-binding advisory vote triggers a formal notice-and-comment rulemaking process that typically requires 12-24 months, with no final FDA determination or published rule reported as of late August 2026. Traders monitor the agency's follow-through on the recommendation, any public comment period developments, and broader policy signals on compounding access versus full drug approval pathways.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Volume
$3,582Data di fine
1 gen 2027Mercato aperto
Jun 22, 2026, 10:10 PM ETRisolutore
0x65070BE91...The FDA's April 2026 reclassification of BPC-157 and 11 other peptides from Category 2 to Category 1 under HHS direction marked the initial step toward potential inclusion on the 503A Bulk Drug Substances List for pharmacy compounding. In July 2026, the Pharmacy Compounding Advisory Committee voted 8-6 to recommend adding BPC-157 despite FDA staff objections citing insufficient human clinical data, limited safety evidence, and immunogenicity risks. This non-binding advisory vote triggers a formal notice-and-comment rulemaking process that typically requires 12-24 months, with no final FDA determination or published rule reported as of late August 2026. Traders monitor the agency's follow-through on the recommendation, any public comment period developments, and broader policy signals on compounding access versus full drug approval pathways.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti